-
Recent Posts
Categories
- Anesthesiology
- Avandia
- Biomedical Engineering
- Cardiology
- Clinical Trials
- Clinics
- Consumer Products
- Counterfeit Products
- Critical Care Medicine
- Dentistry
- Dermatology
- Emergency Rooms
- Endocrinology
- Eye Care
- Family Practice
- FDA 2011
- FDA 2012
- FDA 2013
- FDA Label Change
- FDA Notice
- FDA Recall
- FDA Safety Communication
- FDA Warning
- Gastroenterology
- Healthcare Professionals
- Hematology
- Home Care
- Hospitals
- Infectious Disease
- Internal Medicine
- Laboratory
- multiple sclerosis (MS)
- Nephrology
- Neurology
- Nursing
- OBGYN
- Oncology
- Ophthalmology
- Orthopaedic Surgery
- Pain Management
- Patients
- Pediatrics
- Pharmacy
- Physical Medicine
- Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Risk Manager
- Surgery
- Uncategorized
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
Category Archives: Oncology
Kadcyla ado-trastuzumab emtansine Drug Safety Communication
Kadcyla (ado-trastuzumab emtansine): Drug Safety Communication – Potential Medication Errors Resulting from Name Confusion AUDIENCE: Risk Manager, Pharmacy, Oncology ISSUE: The FDA notified health care professionals that the use of the incorrect nonproprietary name for the breast cancer drug Kadcyla … Continue reading
Incretin Mimetic Drugs for Type 2 Diabetes
Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication – Reports of Possible Increased Risk of Pancreatitis and Pre-cancerous Findings of the Pancreas AUDIENCE: Gastroenterology, Endocrinology, Oncology, Patient ISSUE: FDA is evaluating unpublished new findings by a group of … Continue reading
Posted in Endocrinology, FDA 2013, FDA Warning, Gastroenterology, Oncology, Patients
Tagged drug risks, Endocrinology, FDA warning, Gastroenterology, Incretin Mimetic Drugs, Incretin Mimetic Drugs for Type 2 Diabetes, Oncology, Patient, Type 2 Diabetes
Comments Off
Ondansetron Zofran IV Dose Safety Communication
Ondansetron (Zofran) 32 mg, Single Intravenous (IV) Dose: Updated Safety Communication – Product Removal due to Potential For Serious Cardiac Risks AUDIENCE: Oncology, Surgery, Health Professional ISSUE: FDA is notifying health care professionals that the 32 mg, single intravenous (IV) … Continue reading
Posted in FDA 2012, FDA Safety Communication, Healthcare Professionals, Oncology, Surgery
Tagged drug risks, FDA notice, Health Professional, IV Dose, Oncology, Ondansetron, Ondansetron (Zofran) 32 mg, Ondansetron Zofran IV Dose Safety Communication, Safety Communication, Single Intravenous (IV) Dose, Surgery, Zofran
Comments Off
Leucovorin Calcium Injection Bedford Laboratories Recall
Leucovorin Calcium Injection (Bedford Laboratories): Recall – Visible Particulate Matter AUDIENCE: Pharmacy, Risk Manager, Oncology ISSUE: Bedford Laboratories issued a nationwide recall of three lots of Leucovorin Calcium Injection, due to the discovery of visible crystalline particulate matter in a … Continue reading
Posted in FDA 2012, FDA Recall, Oncology, Pharmacy, Risk Manager
Tagged Bedford Laboratories, drug risks, FDA recall, Leucovorin Calcium Injection, Leucovorin Calcium Injection Bedford Laboratories Recall, Oncology, Pharmacy, Recall, Risk Manager
Comments Off
Ondansetron Zofran IV Drug Safety Communication QT prolongation
Ondansetron (Zofran) IV: Drug Safety Communication – QT prolongation AUDIENCE: Oncology, Surgery, Gastroenterology ISSUE: The U.S. Food and Drug Administration (FDA) is informing healthcare professionals and the public that preliminary results from a recently completed clinical study suggest that a … Continue reading
Posted in FDA 2012, FDA Safety Communication, Gastroenterology, Oncology, Surgery
Tagged drug risks, Drug Safety Communication, FDA Drug Safety Communication, FDA notice, Gastroenterology, Oncology, Ondansetron Zofran IV, Ondansetron Zofran IV Drug Safety Communication QT prolongation, QT prolongation, Surgery
Comments Off
Altuzan bevacizumab Counterfeit Product
Altuzan (bevacizumab): Counterfeit Product – Contains no Active Ingredient ISSUE: FDA lab tests have confirmed that a counterfeit version of Roche’s Altuzan 400mg/16ml (bevacizumab),an injectable cancer medication, found in the U.S. contains no active ingredient. Even if the identified … Continue reading
Posted in Family Practice, FDA 2012, FDA Recall, FDA Warning, Healthcare Professionals, Oncology, Patients
Tagged Altuzan, Altuzan bevacizumab Counterfeit Product, bevacizumab, Cancer Drugs, Counterfeit Product, drug risks, Family Practice, FDA recall, FDA warning, Oncology, or Ban Dune Marketing Inc, Recall, Richards Pharma, Richards Services, Roche’s Altuzan 400mg/16ml, Unapproved Drug, Warwick Healthcare Solutions
Comments Off
Avastin bevacizumab Counterfeit Product
Avastin (bevacizumab): Counterfeit Product – FDA Issues Letters to 19 Medical Practices AUDIENCE: Oncology, Pharmacy, Patient ISSUE: The FDA is warning healthcare professionals and patients about a counterfeit version of Avastin 400mg/16mL, which may have been purchased and used by … Continue reading
Posted in FDA 2012, FDA Warning, Oncology, Pharmacy
Tagged Avastin, Avastin bevacizumab Counterfeit Product, bevacizumab, Cancer Drugs, Counterfeit Product, drug risks, FDA warning, Genetech, Montana Health Care Solutions, Oncology, Pharmacy, Quality Specialty Products, Roche
Comments Off
Treanda bendamustine HCL Recall
Treanda (bendamustine HCL): Recall – Particulate Matter in Vial AUDIENCE: Risk Manager, Oncology, Pharmacy ISSUE: Cephalon, Inc. notified healthcare professionals of a recall of Treanda (bendamustine HCL) for Injection 25mg/8mL, lot TB30111, expiration date 12/2012. This product lot is being … Continue reading
Posted in FDA 2012, FDA Recall, Oncology, Pharmacy, Risk Manager
Tagged bendamustine HCL, Cephalon, chronic lymphocytic leukemia (CLL), drug risks, FDA recall, indolent B-cell non-Hodgkin’s lymphoma (NHL), Oncology, Pharmacy, Recall, Treanda, Treanda bendamustine HCL Recall
Comments Off
Adcetris (brentuximab vedotin) Drug Safety Communication
Adcetris (brentuximab vedotin): Drug Safety Communication – Progressive Multifocal Leukoencephalopathy and Pulmonary Toxicity AUDIENCE: Oncology, Hematology, Neurology ISSUE: FDA notified healthcare professionals that two additional cases of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection that can result in … Continue reading
Posted in FDA 2011, FDA Label Change, FDA Notice, FDA Warning, Hematology, Neurology, Oncology
Tagged Adcetris, Adcetris (brentuximab vedotin) Drug Safety Communication, brentuximab vedotin, drug risks, Drug Safety Communication, FDA notice, FDA warning, Progressive Multifocal Leukoencephalopathy, Pulmonary Toxicity, safety label changes
Comments Off
Sprycel (dasatinib) Drug Safety Communication
Sprycel (dasatinib): Drug Safety Communication – Risk of Pulmonary Arterial Hypertension AUDIENCE: Hematology, Oncology ISSUE: FDA notified healthcare professionals that Sprycel (dasatinib) may increase the risk of a rare but serious condition in which there is abnormally high blood pressure … Continue reading
Posted in FDA 2011, FDA Notice, Hematology, Oncology
Tagged dasatinib, FDA notice, Hematology, Oncology, Risk of Pulmonary Arterial Hypertension, Sprycel, Sprycel (dasatinib)
Comments Off